Cargando…
Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids
Cardiovascular diseases (CVD) remain the leading cause of death across the globe, hence, establishing strategies to counteract CVD are imperative to reduce mortality and the burden on health systems. Dietary modification is an effective primary prevention strategy against CVD. Research regarding die...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672651/ https://www.ncbi.nlm.nih.gov/pubmed/37999373 http://dx.doi.org/10.3390/md21110549 |
_version_ | 1785140441383960576 |
---|---|
author | Caffrey, Cliodhna Leamy, Anna O’Sullivan, Ellen Zabetakis, Ioannis Lordan, Ronan Nasopoulou, Constantina |
author_facet | Caffrey, Cliodhna Leamy, Anna O’Sullivan, Ellen Zabetakis, Ioannis Lordan, Ronan Nasopoulou, Constantina |
author_sort | Caffrey, Cliodhna |
collection | PubMed |
description | Cardiovascular diseases (CVD) remain the leading cause of death across the globe, hence, establishing strategies to counteract CVD are imperative to reduce mortality and the burden on health systems. Dietary modification is an effective primary prevention strategy against CVD. Research regarding dietary supplementation has become increasingly popular. This review focuses on the current in vivo, in vitro, and epidemiological studies associated with that of omega-3 polyunsaturated fatty acids (n-3 PUFAs) and polar lipids (PLs) and how they play a role against CVD. Furthermore, this review focuses on the results of several major clinical trials examining n-3 PUFAs regarding both primary and secondary prevention of CVD. Notably, we place a lens on the REDUCE-IT and STRENGTH trials. Finally, supplementation of PLs has recently been suggested as a potential alternative avenue for the reduction of CVD incidence versus neutral forms of n-3 PUFAs. However, the clinical evidence for this argument is currently rather limited. Therefore, we draw on the current literature to suggest future clinical trials for PL supplementation. We conclude that despite conflicting evidence, future human trials must be completed to confirm whether PL supplementation may be more effective than n-3 PUFA supplementation to reduce cardiovascular risk. |
format | Online Article Text |
id | pubmed-10672651 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106726512023-10-24 Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids Caffrey, Cliodhna Leamy, Anna O’Sullivan, Ellen Zabetakis, Ioannis Lordan, Ronan Nasopoulou, Constantina Mar Drugs Review Cardiovascular diseases (CVD) remain the leading cause of death across the globe, hence, establishing strategies to counteract CVD are imperative to reduce mortality and the burden on health systems. Dietary modification is an effective primary prevention strategy against CVD. Research regarding dietary supplementation has become increasingly popular. This review focuses on the current in vivo, in vitro, and epidemiological studies associated with that of omega-3 polyunsaturated fatty acids (n-3 PUFAs) and polar lipids (PLs) and how they play a role against CVD. Furthermore, this review focuses on the results of several major clinical trials examining n-3 PUFAs regarding both primary and secondary prevention of CVD. Notably, we place a lens on the REDUCE-IT and STRENGTH trials. Finally, supplementation of PLs has recently been suggested as a potential alternative avenue for the reduction of CVD incidence versus neutral forms of n-3 PUFAs. However, the clinical evidence for this argument is currently rather limited. Therefore, we draw on the current literature to suggest future clinical trials for PL supplementation. We conclude that despite conflicting evidence, future human trials must be completed to confirm whether PL supplementation may be more effective than n-3 PUFA supplementation to reduce cardiovascular risk. MDPI 2023-10-24 /pmc/articles/PMC10672651/ /pubmed/37999373 http://dx.doi.org/10.3390/md21110549 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Caffrey, Cliodhna Leamy, Anna O’Sullivan, Ellen Zabetakis, Ioannis Lordan, Ronan Nasopoulou, Constantina Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids |
title | Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids |
title_full | Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids |
title_fullStr | Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids |
title_full_unstemmed | Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids |
title_short | Cardiovascular Diseases and Marine Oils: A Focus on Omega-3 Polyunsaturated Fatty Acids and Polar Lipids |
title_sort | cardiovascular diseases and marine oils: a focus on omega-3 polyunsaturated fatty acids and polar lipids |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672651/ https://www.ncbi.nlm.nih.gov/pubmed/37999373 http://dx.doi.org/10.3390/md21110549 |
work_keys_str_mv | AT caffreycliodhna cardiovasculardiseasesandmarineoilsafocusonomega3polyunsaturatedfattyacidsandpolarlipids AT leamyanna cardiovasculardiseasesandmarineoilsafocusonomega3polyunsaturatedfattyacidsandpolarlipids AT osullivanellen cardiovasculardiseasesandmarineoilsafocusonomega3polyunsaturatedfattyacidsandpolarlipids AT zabetakisioannis cardiovasculardiseasesandmarineoilsafocusonomega3polyunsaturatedfattyacidsandpolarlipids AT lordanronan cardiovasculardiseasesandmarineoilsafocusonomega3polyunsaturatedfattyacidsandpolarlipids AT nasopoulouconstantina cardiovasculardiseasesandmarineoilsafocusonomega3polyunsaturatedfattyacidsandpolarlipids |